On the recordApril 26, 2016
I do question how Valeant can justify, financially and morally, increasing the price of Syprine since it is an old drug, out of patent, and had been reasonably priced until they began manufacturing it.
Source
congress.govI do question how Valeant can justify, financially and morally, increasing the price of Syprine since it is an old drug, out of patent, and had been reasonably priced until they began manufacturing it.
Senator Casey questions Valeant's price increase of an old drug.
Share
More from Bob Casey
We are enormously grateful for leaders like Senator Casey who are working to make those investments a reality.
They're selling you a lie. It's in the bag with the diapers. Prices are up because these corporations are scheming to drive them up.
I am disappointed that Dr. de la Torre defied the subpoena this Committee authorized and has chosen not to appear today.